// App-Quantinova.ai

1556 : Weight based ribavirin with sofosbuvir and daclatasvir for 12 weeks for patients with Genotype 3 Hepatitis C and cirrhosis: An analysis of efficacy and long‐term clinical outcomes

Researchers

Presenter

  • Chiara Mazzarelli

Principal Investigators

  • Kate Childs

  • Sarah Montague

  • Geoffrey M. Dusheiko

  • Kosh Agarwal

  • Mary Cannon

Medical Centers

  • Institute of Liver Studies, Kings CollegeHospital NHS Trust, London , United Kingdom

  • Hepatology and Gastroenterology Unit, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy

Locations

  • United Kingdom

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Hepatitis C

  • Cirrhosis

Biomarkers

  • N/A

Drug/Treatment

  • daclatasvir

  • Sofosbuvir

  • Ribavirin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved